Condition
Epithelial Malignancies
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
100.0%
2 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Terminated2
Clinical Trials (2)
Showing 2 of 2 trials
NCT01313429Phase 1Terminated
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
NCT01341496Phase 1Terminated
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Showing all 2 trials